Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY-NC-ND 4.0eBioMedicine

Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy

Related

  1. In situ-activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy
    Xin-Ge Wang, Yue-Lan Huang, Xuan-Ren Shi +3
    iSciencePeer-reviewedCC BY 4.0Full textImmunologyMicrobiologyCell PressCrossrefPMC
  2. A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I
    Chuyu Huang, Yun Ye, Yi Guo +7
    ExplorationPeer-reviewedCC BY 4.0Full textOncologyPMC
  3. Cellular immunotherapy for lung cancer: current clinical evidence, translational challenges, and future perspectives: a narrative review
    Nannan Ma, Chunxiang Shang
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
    Xianye He, Jiao He, Zhongsong Zhang +6
    International Journal of NanomedicinePeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Chimeric antigen receptor-engineered cell therapy for asthma: advances in targeting type 2 inflammation and translational challenges
    Yifei Niu, Chenyang Jian, Peize Liu +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
BibTeX
@article{liu2026senescencetargeted,
  title = {{Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy}},
  author = {Jiayu Liu and Wenxia Shao and Qing Ye},
  journal = {eBioMedicine},
  year = {2026},
  month = nov,
  doi = {10.1016/j.ebiom.2026.106540},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S235239642600424X},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy
AU  - Jiayu Liu
AU  - Wenxia Shao
AU  - Qing Ye
PY  - 2026
DA  - 2026/11/10
JO  - eBioMedicine
DO  - 10.1016/j.ebiom.2026.106540
UR  - https://linkinghub.elsevier.com/retrieve/pii/S235239642600424X
SN  - 2352-3964
ER  -